Paper Details

  1. Home
  2. Paper Details

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.

Author: BrinsonCynthia, ChuckSusan, CohenCalvin J, De-OertelShampa, EsserStefan, GarnerWill, HaasBernhard, SmithDon E, ThorpeDavid, TrottierBenoit, WilkinsEd L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This 96-week, randomized, open-label study compared the efficacy and safety of two single-tablet regimens for treatment-naïve HIV-1-infected adults: rilpivirine (RPV) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and efavirenz (EFV) + FTC/TDF. The study found that both regimens were associated with high adherence, high treatment satisfaction, and improved quality of life. However, RPV/FTC/TDF was associated with fewer treatment-emergent adverse events and patient-reported symptoms.
Paper Details　
Original Abstract of the Article :
This 96-week, randomized, open-label study was designed to assess the efficacy and safety of two single-tablet regimens in treatment naïve HIV-1-infected adults: rilpivirine (RPV) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and efavirenz (EFV) + FTC/TDF. Assessments included patient-repo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/09540121.2015.1096890

データ提供：米国国立医学図書館（NLM）

Single-Tablet Regimen: A Patient-Centered Approach to HIV Treatment

The treatment of HIV has advanced dramatically, traversing a vast desert of scientific discovery. This study, like a camel caravan carrying vital supplies, evaluates the efficacy and safety of two single-tablet regimens for treatment-naive adults with HIV-1. The researchers, using a rigorous randomized, open-label design, compared the impact of rilpivirine/emtricitabine/tenofovir disoproxil fumarate with efavirenz/emtricitabine/tenofovir disoproxil fumarate on patient-reported outcomes.

Patient-Reported Outcomes: A Key to Success in HIV Treatment

This study highlights the importance of patient-centered care in HIV treatment. The researchers, recognizing the critical role of patient experience, assessed medication adherence, quality of life, treatment satisfaction, and HIV-related symptoms. The results show that both single-tablet regimens were associated with high adherence, satisfaction, and improved quality of life. It’s like a camel caravan finding a comfortable campsite – a positive experience that promotes well-being.

Navigating the Desert of HIV Treatment

The findings of this study offer valuable insights for clinicians treating HIV-infected individuals. The use of single-tablet regimens, like a well-organized caravan, simplifies treatment and improves patient adherence. This study underscores the importance of considering the patient's perspective and promoting their overall well-being in the treatment process.

Dr.Camel's Conclusion

This study showcases the patient-centered approach to HIV treatment, demonstrating that single-tablet regimens can enhance adherence, satisfaction, and quality of life. As we continue our journey through the desert of HIV research, we must remain focused on patient well-being and strive to develop even better treatment options.

Date :
  1. Date Completed 2016-09-06
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

26489045

DOI: Digital Object Identifier

10.1080/09540121.2015.1096890

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.